Tower Research Capital LLC (Trc) Mi Nk Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,401 shares of INKT stock, worth $55,630. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,401
Previous 4,027
34.12%
Holding current value
$55,630
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding INKT
# of Institutions
24Shares Held
810KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$2.41 Million0.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$1.72 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny102KShares$1.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.1KShares$989,9630.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$898,1180.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $348M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...